Pfizer has a lot going on these days: It’s developing Omicron booster shots, plans to test its Covid pill, Paxlovid, in children younger than 12, and it’s on the hunt for deals.
What do all of those things have to do with each other? They will all fall under the remit, entirely or in part, of the company’s new chief development officer, William Pao, who Pfizer announced Tuesday it had hired from Roche, where he was head of early research.
Create a display name to comment
This name will appear with your comment